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Cytokine profile of obese asthma phenotype 
 
INTRODUCTION 
The prevalence of obesity (body mass index (BMI) 
>30 kg/m2) has increased dramatically in the recent 
decades and it is becoming pandemic worldwide.1,2 
Asthma is also a major health problem affecting 
about 300 million people in the world and there 
may be an additional 100 million persons with 
asthma by 20253.The prevalence of bronchial 
asthma in the Nile Delta region of Egypt was found 
to be 7.7%4. 
Numerous epidemiologic studies published 
during the past decade have demonstrated an 
increased risk of asthma and asthma-like symptoms 
in obese individuals with a dose response effect of 
increasing BMI on asthma incidence5.Furthermore, 
it is known that obesity may worsen pre-existing 
asthma, through both biochemical and mechanical 
effects, and potentially impair response to 
treatment6.In addition, preliminary data suggest that 
obese patients with asthma demonstrate different 
asthma phenotypes compared with patients of 
normal weight7. 
The adipose tissue was recognized as an active 
endocrine organ that can affect the function of other 
organs and as an important source of several 
proinflammatory cytokines, chemokines, growth 
factors and adipokines like leptin, adiponectin and 
resistin8.Many adipokines including TNF-α, IL-6, 
plasminogen activator inhibitor 1, eotaxin, vascular 
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endothelial growth factor (VEGF) and monocyte 
chemotactic protein (MCP)-1 have been associated 
with asthma9 and could play a role in the 
relationship between obesity and asthma. In 
addition, plasma levels of C-reactive protein (CRP), 
an acute-phase protein that is elevated in 
inflammation, and IL-6 levels are both negatively 
correlated with plasma adiponectin levels10. 
Hence, this study was undertaken to compare 
pulmonary function tests (PFTs), C-reactive protein 
(CRP), and inflammatory cytokines in both obesity 
and asthma in Egyptian adolescents.  
 
METHODS 
This study is a cross-sectional, controlled study.  A 
total of 30 healthy controls (16 females and 14 
males) and 50 adolescent severe asthmatic subjects 
(25 females and 25 males) aged 18 years old were 
evaluated and each was divided into two subgroups 
using BMI classification11. Asthmatic lean group 
had 25 patients (13 males and 12 females) with 
BMI <25.0 kg/m2 and asthmatic obese group had 25 
patients (12 males and 13 females) with BMI > 30.0 
kg/m2. Control lean group had 15 subjects (7 
females and 8 males) with BMI <25.0 kg/m2, and 
control obese group had 15 subjects (9 females and 
6 males) with BMI > 30.0 kg/m2. All patients had a 
clinical diagnosis of allergic severe asthma as 
follows:  
1) Reversibility was assessed after administration 
of 200- 400 μg albuterol by spacer device. 
2) Atopy was defined as 3 mm greater than control 
on skin prick testing or detection of specific IgE to 
one or more of Dermatophagoides Pteronyssinus, 
grass, trees, cat, dog or Aspragillus fumigates. 
3) International ERS/ATS guidelines on definition, 
evaluation and treatment of severe asthma 12 
Informed consents for all participating 
individuals were obtained. The protocol of the 
study was approved by the institutional ethical 
committee. 
Patients and controls underwent the following: 
1- Specific allergological examination which 
included the collection of relevant medical history 
2- Body mass index calculation as weight (Kg)/ 
height (m2). 
3- Pulmonary function tests : forced expired 
volume in one second(FEV1),forced vital capacity 
(FVC), FEV1/VC and peak expiratory flow (PEF) 
measured by spirometry (Micro Medical® Spiro 
USB) 
Measurement of serum hsCRP, leptin, TNF-α, 
IL-5 and IL-6 by ELISA: Peripheral blood was 
collected from fasting participants in the morning. 
Serum levels were determined by using 




Data were processed and analyzed using the 
Statistical Package of Social Science (Version 15; 
SPSS, Inc., Chicago, IL). Normality tests were done 
using the Shapiro test. The data were presented as 
mean ± standard deviation (SD).   ANOVA test was 
used to compare the four groups followed by 
pairwise comparisons using least significant 
difference (LSD) test. Correlation matrix and 
coefficient of correlation were done using Pearson's 
correlation coefficient. Chi-square test and fisher’s 
exact test were used in case of low expected values. 
A p-value less than 0.05 was taken as the threshold 
of statistical significance.  
 
RESULTS 
Demographic characteristic of the studied groups 
are shown in table 1.  
 Analysis of serum levels of IL-6, TNF-α and 
leptin in the 4 studied groups revealed significantly 
higher levels (p<0.01) in obese subgroups whether 
asthmatic or control compared to the lean 
subgroups (Table 2). Furthermore, serum levels of 
IL-6, TNF-α and leptin showed a significant 
positive linear correlation with BMI in the 4 studied 
subgroups (Table2).      
Serum CRP showed significant increase 
(p<0.01) in asthmatic obese compared to the other 3 
subgroups (asthmatic lean, control lean and control 
obese). Also, it showed significant increase 
(p=0.04) in asthmatic lean compared to their lean 
controls (Table 2).  In addition, serum CRP showed 
significant positive linear correlation with BMI in 
the 4 studied groups (Table 3). 
Asthmatic patients whether obese or lean 
showed significant increase in the mean serum level 
of IL-5 compared to control obese or lean, whereas 
non-significant difference was found in serum level 
of  IL-5 between obese and lean asthmatics (Table 
2). In addition, significant negative correlations 
were found between serum IL-5 with all studied 
parameters of pulmonary function (FEV1, FVC, 
FEV1 /FVC ratio, and PEF %) (Table4). 
The values of forced expiratory volume in 1 
second (FEV1), forced vital capacity (FVC), FEV1 
/FVC rate, and peak expiratory flow (PEF %) of 
predicted were found to be significantly lower in 
asthmatics (lean and obese) than in controls (lean 
and obese) (p<0.001); however, the lean asthmatics  
were comparable to the obese ones (Table 5).
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 No. % No. % No. % No. % 
Sex 
Female 12 48% 13 52% 7 46.67% 9 60% 0.76 0.90 Male 13 52% 12 48% 8 53.33% 6 40% 
BMI Classification 
Class 1 obesity 0 0% 12 48% 0 0% 2 13.33% 
94.33 0.00 
Class 2 obesity 0 0% 7 28% 0 0% 5 33.33% 
Class 3 obesity 0 0% 2 8% 0 0% 3 20% 
healthy weight 23 92% 0 0% 15 100% 0 0% 
overweight 0 0% 4 16% 0 0% 5 33.3% 
underweight 2 8% 0 0% 0 0% 0 0% 
Spirometry 
Normal spirometry 0 0% 0 0% 15 100% 15 100% 
88.12 0.00 
Mild obstruction 7 28% 1 4% 0 0% 0 0% 
Moderate obstruction 3 12% 9 36% 0 0% 0 0% 
Moderately Severe obstruction 6 24% 6 24% 0 0% 0 0% 
Severe obstruction 4 16% 6 24% 0 0% 0 0% 
Very severe obstruction 5 20% 3 12% 0 0% 0 0% 
*Statistical significance was defined as P ≤ 0.05. 
 
 



























obese -11.85 <0.01 - 23.22 <0.01 -16.30 <0.01 -0.80 0.21 - 27.48 <0.01 
Control 
lean 2.73 0.04 0.21 0.96 2.11 0.63 3.30 <0.01 8.68 0.06 
Control 




lean 14.59 <0.01 23.42 <0.01 18.41 <0.01 4.10 <0.01 36.16 <0.01 
Control 




obese -1.75 0.23 - 23.16 <0.01 - 20.87 <0.01 0.74 0.10 - 34.80 <0.01 




Table 3. Pearson’s correlation coefficient of body mass index (BMI) and serum cytokine 















Correlation 0.42 0.68 0.42 -0.01 0.40 
Significance 
(2-tailed) <0.01* <0.01* <0.01* 0.93 <0.01* 
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Table 4. Multiple linear regressions of the four spirometric values with gender, 



















R P R p R P R p R p R p R P 
FEV 1 -0.70 0.49 0.20 0.84 -0.85 0.40 -0.25 0.80 -0.14 0.89 -4.57 <0.001* 0.70 0.48 
FVC% 0.37 0.71 0.31 0.76 -0.69 0.49 -0.22 0.83 0.74 0.46 -1.94 0.05* 0.57 0.57 
FEV1/ 
FVC % -0.71 0.40 0.53 0.60 -0.81 0.42 -0.24 0.81 -0.14 0.89 -4.21 <0.001* 0.71 0.48 
PEF% -0.44 0.66 -0.01 0.99 0.07 0.95 0.15 0.88 -0.19 0.85 -4.71 <0.001* -0.08 0.93 
*Statistical significance was defined as P ≤ 0.05 
BMI: Body mass index; FEV1: Forced Expiratory Volume in 1 second; FVC: Forced Vital 
Capacity; and PEF: Peak Expiratory Flow. 
 
 
Table 5.  Pairwise comparison of the spirometric variables in the four studied subgroups. 
 





Asthmatic obese 2.60 4.24 0.54 
Control lean -36.52 4.89 <0.01 
Control obese -29.65 4.89 <0.01 
Asthmatic 
obese 
Control lean -39.12 4.89 <0.01 
Control obese -32.25 4.89 <0.01 





Asthmatic obese 7.24 4.11 0.08 
Control lean -16.40 4.74 <0.01 
Control obese -11.27 4.74 0.02 
Asthmatic obese Control lean -23.64 4.74 <0.01 Control obese -18.51 4.74 <0.01 




Asthmatic obese -2.28 2.53 0.37 
Control lean -25.01 2.93 <0.01 
Control obese -19.55 2.93 <0.01 
Asthmatic obese Control lean -22.73 2.93 <0.01 Control obese -17.27 2.93 <0.01 





Asthmatic obese -3.04 4.40 0.49 
Control lean -34.36 5.08 <0.01 
Control obese -33.23 5.08 <0.01 
Asthmatic obese Control lean -31.32 5.08 <0.01 Control obese -30.19 5.08 <0.01 
Control lean Control obese 1.13 5.68 0.84 
*Statistical significance was defined as P ≤ 0.05 




Asthma and obesity are growing epidemics in the 
developing and the developed world9.Asthma is a 
syndrome that includes different phenotypes. One 
phenotype which has been suggested in clinical 
studies and identified in cluster analyses is that of 
an “asthma-obesity” phenotype13. Furthermore, 
obesity is a major risk factor for asthma14. The 
mechanistic basis for the association between 
obesity and asthma is not known, although 
mechanical, immunological, genetic, epigenetic, 
hormonal, and environmental pathways have all 
been proposed. However, systemic inflammation in 
obesity could up-regulate the asthmatic pathway, 
and this is modified by the adipokines and other 
systemic inflammatory markers5,13. Adipose tissue 
communicates with other organs through releasing 
important mediators produced by tissue-resident 
macrophages and adipocytes, including tumor 
necrosis factor-α (TNF-α), interleukin 6, and leptin. 
Inflammatory cytokines, asthma and obesity 
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The presence of excess adiposity therefore provides 
a consistent stimulus for chronic, low grade 
systemic inflammation15. 
In our study, serum levels of IL-6, TNF-α and 
leptin were found to be significantly elevated in 
obese versus normal-weight individuals whether 
asthmatic or control. Also, hsCRP was found to be 
significantly higher in asthmatic obese group than 
the other 3 groups (asthmatic lean, control lean and 
control obese) and it was found to be significantly 
higher in the asthmatic lean when compared with 
the lean controls. In addition, these biomarkers (IL-
6, TNF-α, leptin and hsCRP) have shown a 
significant positive correlation with BMI in the 4 
studied groups. Thus, hsCRP could be considered a 
surrogate marker for both obesity and asthma; 
whereas IL-6, TNF-α and leptin could serve as 
surrogate markers for obesity. Although the values, 
notably for TNF-α, leptin, and IL-6, were highest in 
the obese asthmatic group, the differences 
compared with obese non-asthmatic group were not 
significant.  In the current study, obesity measured 
by BMI showed significant positive correlation 
with both CRP and serum levels of IL-6. Since IL-6 
is considered an adipocyte derived interleukin9, thus 
adipose tissue could be considered a dynamic factor 
responsible for the production of a number of 
inflammatory markers (leptin, TNF-α and IL-6) that 
contributes to low grade systemic inflammation15. 
However, these markers are related to obesity rather 
than asthma even though the role of most of them in 
asthma pathogenesis is well defined. Studies to date 
have shown associations between TNF-α, IL-6, 
hsCRP and the obese state. Rexrode et al., found 
that indices of both total and abdominal adiposity 
were strongly associated with significant increased 
levels of CRP and IL-616. Park et al., reported 
higher serum concentrations of TNF-α, IL-6, and 
CRP in obese than in non-obese individuals17. In 
addition, TNF-α, IL-6 and CRP levels were found 
to be positively correlated with adipocyte size18. 
Also Canoz et al., found significant increase in 
serum concentrations of leptin, TNF-α and IL-6 in 
obese asthma patients than in non-obese asthma 
patients19. 
It has also been shown that leptin fulfills an 
important function in stimulating the release of 
proinflammatory cytokines such as IL-6 and TNF-α 
by adipocytes 20. Leptin enhances the Th1 response, 
suppresses Th2 pathways, promotes phagocytosis, 
and proinflammatory cytokine production21,22. Also, 
current evidence suggests that systemic leptin may 
be associated with greater asthma prevalence and/or 
severity. However, its definite role in asthma 
pathogenesis is still evolving23. 
TNF-α is expressed in and secreted by adipose 
tissue24. The metabolic effects of TNF-α in obesity 
have several potential mechanisms such as 
influencing gene expression, and impairing insulin 
signaling25. Levels of TNF-α have been found to be 
significantly higher in obese children and 
adolescents compared to non-obese subjects10,15. On 
the other hand, TNF-α   contributes to inflammatory 
response in asthma by different ways. It induces 
histamine release from human mast cells, 
potentiates human mast cells cytokine secretion, 
increases the cytotoxic effect of eosinophils on 
endothelial cells and is involved in the activation of 
and cytokine release by T cells. Besides, it 
increases epithelial expression of adhesion 
molecules and is a chemo attractant for neutrophils 
and eosinophils 26. Emerging evidence suggests that 
it may play an important role in severe, refractory 
asthma27. Increased TNF-α levels in BAL are 
associated with increased levels of remodeling in 
patients with asthma and inhibiting TNF-α reduces 
asthma exacerbation, further suggesting that TNF-α 
may be related to airway remodeling28.Interestingly, 
the TNF-α gene lies within the asthma linkage 
regions on 6p, and several studies have found 
associations between the 308-G/A polymorphism of 
the TNF-α gene (TNF, 6p21,3) and both asthma and 
obesity29-31. 
IL-6 expression by adipose tissue and circulating 
IL-6 concentrations are positively correlated with 
obesity. IL-6 contributes to inflammation in obesity 
by impairing insulin signalling, and suppressing 
adiponectin production25. Also, it leads to the 
synthesis of C-reactive protein (CRP), which 
exacerbates the inflammatory response19. Multiple 
cross-sectional studies have identified significantly 
elevated levels of IL-6 in obese compared to non-
obese children and adolescents. On the other hand, 
IL-6 is involved in the acute-phase and late-phase 
asthma response and correlates with asthma disease 
activity15. IL-6 promotes the differentiation of Th2 
cells by enhancing endogenous IL-4 production by 
CD4 T cells. It promotes IL-13 production which 
causes mucus hyper secretion by airway epithelial 
cells and TH-17 differentiation. It also inhibits Th-1 
differentiation, blocks T-reg cells activity32 and 
promotes subepithelial fibrosis in animal models. 
Hence, it may be a key modulator of airway 
remodelling in asthma33. In addition, 
polymorphisms at the -174 position of the IL-6 
gene were found to be associated with both obesity 
and asthma susceptibility34,35. Thus IL-6 and TNF-α 
as biomarkers of obesity could add to asthma 
severity through enhancing airway remodelling. 
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IL-5 has been recognized as the most specific 
cytokine in the eosinophil lineage and has been 
identified as the key common denominator in 
inflammatory pathways in asthma36. In the current 
study, serum IL-5 levels were significantly elevated 
in asthmatic individuals (obese/lean) in comparison 
to control group (obese/lean) with non-significant 
correlation with BMI. Although the highest levels 
occurred in the obese asthmatic group, the 
differences compared with non-obese subjects with 
asthma were not statistically significant. Also, IL-5 
levels showed a significant negative correlation 
with FEV1%. So, IL-5 is markedly correlated with 
asthma and its severity rather than obesity. It was 
previously shown that IL-5 deficiency profoundly 
impairs visceral adipose tissue eosinophil 
accumulation and results in increased adiposity and 
insulin resistance 37. However, in our study IL-5 
was markedly elevated in asthmatic obese group 
compared to control obese group which could be 
explained by an add-on effect of asthma in obese 
patients. 
The most consistently reported effect of obesity 
on lung function is a decrease in the functional 
residual capacity (FRC) and expiratory reserve 
volume (ERV)21. Spirometric variables, such as 
FEV1 and FVC, tend to decrease with increasing 
BMI. However, the effect is small, and both FEV1 
and FVC are usually within the normal range in 
healthy, obese adults and children. The FEV1-to-
FVC ratio is usually well preserved or increased. 
This indicates that the major effect of obesity is on 
lung volumes, with no direct effect on airway 
obstruction38. 
In the current study, the FEV1/FVC ratio in 
obese asthmatics was 61.80 ± 10.26%, thus 
showing a reduced ratio compared to non-obese 
asthmatics yet the difference was non-significant. 
These findings agree with those of, Ramasamy et 
al.9, Scott et al.39 and Lessard et al.40. 
In conclusion, it is obvious that there was a 
definite interaction between asthma and obesity, 
with regards to inflammation. The intensity of 
airway inflammation could be relatively greater in 
obese asthmatic patients through increased levels of 
obesity biomarkers (TNF-α, IL-6, CRP and leptin), 
suggesting a synergistic effect of obesity on 
existing airway inflammation. The fact that serum 
levels of TNF-α, IL-6, and leptin were higher in 
obese participants compared to those with normal 
weight while Th-2 related biomarker (IL-5) was 
markedly higher in asthmatic individuals compared 
to controls indicate that TNF-α, IL-6, and leptin 
fundamentally originate from obesity and could 
better reflect inflammatory activity in obese 
individuals; whereas IL-5 is derived mainly from 
asthma. However, it is difficult to judge whether 
one or a group of cytokines in isolation are of 
importance in a particular disease pathogenesis. In 
all the settings, obesity seems to have complex 
effects on the pathogenesis of airway disease in 
asthma. Further large-scale, gene-based studies are 
required in order to better clarify the relationship 
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